Citigroup Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $50

Citigroup analyst Eric Joseph initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Buy rating and announces Price Target of $50.